BioTech two weeks ago
28.5 million for Munich family doctor Startup AVI Medical
The Munich Health Startup AVI Medical has completed a round of financing over 28.5 million euros.
This was cited by the Berlin HealthTech Fund Heal Capital and the New York investor addition. In addition, the Investor Picus Capital, Vorwerk Ventures, ID Invest, 3VC and Claret Capital Partners participated as well as several business angels.
The startup, founded by Vlad Lata, Christoph Baumeister and Julian Kley, operates family doctoral practices, which are intended to expand the doctor-patient contact with modern digital possibilities, for example online appointment, digital history or telemedicine. So far there are three locations in Munich.
E-Commerce-Software Circuly erhält 1,3 Millionen | GS Startup-Ticker - Business Insider
Alles, was man über Startups wissen muss. Auf einen Blick. Die Kurznachrichten aus der Szene könnt ihr hier verfolgen.
Antidote Technologies Raises $23M in Funding
Antidote Technologies, a US and UK based digital health company, raised $23M in funding.
The round was led by LBO France, which is investing $10m through its Digital Health 2 fund, with participation from existing investors Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures, who are investing $13.2m in total. In conjunction with the funding, Sebastien Woynar and Franck Noiret of LBO France will join the Antidote Board as a director and an observer, respectively.
The company intends to use the funds to enhance its clinical trial search engine, launch new products and services (including data insights), and expand its presence internationally.
Led by Laurent Schockmel, CEO, Antidote is a digital health company which uses precision recruitment to match the right patients with the right trials. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in New York, NY, Carmel, IN, and London, U.K.
Antidote Technologies Raises $23M in Funding | FinSMEs
Antidote Technologies, a US and UK based digital health company, raised $23M in funding
Amyl Therapeutics Raises €18.3M in Series A Funding
Amyl Therapeutics, a Liege, Belgium-based preclinical biotechnology company, raised €18.3M in Series A funding.
The round is comprised of:
- €8.6m in equity led by Noshaq – a regional Belgian private-public fund – with participation from Merieux Participations, Sambrinvest and other private investors; and
- €9.7m in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.
Following the closing of the financing, Dr. Pierre Vandepapelière (Amyl’s Co-Founder, CEO and CMO), Florent Gros (Amyl’s Co-Founder and Chairman), Dr. Valérie Calenda (Managing Partner at Merieux Equity Partners), Kenneth Buckfire (President of Miller Buckfire & Co.) and Amel Tounsi (Investment Manager at Noshaq) have joined the Board of Directors.
The company will use the funds to progress the discovery and preclinical development of therapeutic candidates that are able to target multiple misfolded proteins implicated in both progressive peripheral and neurodegenerative rare diseases.
Founded in November 2020 by Drs. Florent Gros and Pierre Vandepapelière, Chief Executive Officer and Chief Medical Officer, and also led by Dr. Karine Goraj, Chief Scientific Officer (CSO), Amyl Therapeutics is a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis.
Amyl Therapeutics Raises €18.3M in Series A Funding | FinSMEs
Amyl Therapeutics, a Liege, Belgium-based preclinical biotechnology company, raised €18.3M in Series A funding
Qumata Closes $10M Series A Funding
Qumata (fka HealthyHealth Group), a London, UK-based life and health insurance underwriting tech company, closed a $10m Series A financing.
The round was led by MMC Ventures with participation from AdirVentures and a number of other family offices, as well as existing investors including TMT Investments PLC.
The company intends to use the funds to accelerate global expansion of the current offering, after launching the product commercially with multiple large, listed insurers in Europe, Asia Pacific, the UK and North America.
Led by Luca Schnettler, CEO, Qumata is a building a Life and Health Insurance Underwriting company that uses digital data (about individual health and wellbeing through mobile devices and wearables) to calculate the risk of diagnosis for over 800 conditions, along with Extra Mortalities and Morbidities, saving applicants hours filling out long questionnaires or visiting the doctor.
Qumata Closes $10M Series A Funding | FinSMEs
Qumata (fka HealthyHealth Group), a London, UK-based life and health insurance underwriting tech company, closed a $10m Series A financing
Transine Therapeutics Raises £9.1 in Funding
Transine Therapeutics, a Cambridge UK-based biotechnology company which specializes in development of therapeutic RNAs, closed £9.1 in funding.
The round was led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF). In conjunction with the financing, Rob Woodman, Senior Partner at Takeda Ventures, and Christian Jung, Partner at the DDF joined Transine’s Board.
The company intends to use the funds to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics, initially focused on the Central Nervous System and Ophthalmology applications.
Founded in 2020, Transine Therapeutics is a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology. Transine is based on the work of geneticists Professors Stefano Gustincich and Piero Carninci, who identified a new functional and naturally occurring class of long non-coding RNAs, named SINEUPs. The technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.
Transine Therapeutics Raises £9.1 in Funding
Transine Therapeutics, a Cambridge UK-based biotechnology company which specializes in development of therapeutic RNAs, closed £9.1 in funding
moveUP Secures €3.65M in Financing
moveUP, a Belgian company specialized in remote digital care before and after orthopaedic and bariatric surgeries, raised €3.65m in funding.
The round was co-led by Karista and White Fund, in an international consortium with Nina Capital (Spain), CAREvolution (Belgium) and Qbic (Belgium), and historical investors.
The company intends to use the funds to further develop its solution and accelerate its international expansion.
Founded in 2015, moveUP is a digital therapeutics company combining the development of medical technologies, as well as providing care. The company develops data-driven personalized remote digital care for post-acute out-patients, delivering similar clinical outcomes at a lower cost, while enabling healthcare professionals to focus on more complex patients or urgent situations. It does so by providing validated and (semi)-automated value-based treatment plans on an integrated multimodal platform, managed by local care teams and supported by moveUP’s virtual clinic, providing 24/7 expert support. moveUP has offices in Brussels and Ghent where 25 people are employed.
moveUP Secures €3.65M in Financing | FinSMEs
moveUP, a Belgian company specialized in remote digital care before and after orthopaedic and bariatric surgeries, raised €3.65m in funding
RheaVita Raises €2.5M in Series A Funding
RheaVita, a Ghent, Belgium-based provider of freeze-drying technology for biopharmaceutical products, raised €2.5M in Series A funding.
The round was led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.
The company intends to use the funds to build a GMP compliant biopharmaceutical continuous, controlled, freeze-drying production line and accelerate commercialization of its technology.
Founded in 2018 as a spin-out of Ghent University and led by Jos Cover, CTO, and Prof. Dr. Thomas De Beer, CEO, RheaVita has developed a continuous freeze-drying solution to address biopharmaceutical product development, manufacturing and supply needs in order to reach patients. Its patented continuous freeze-drying technology integrates all the traditional freeze-drying process steps into one continuous production line to allow pharmaceutical companies to achieve rapid product and process development, and manufacturing cycles with controlled product quality. The technology enables both centralized large volume and decentralized low-volume-high-value product manufacturing and is suited for innovative biological therapies, such as gene therapy, RNA based therapies, antibodies, vaccines, and to produce precision medicines and drug products for rare diseases.
RheaVita Raises €2.5M in Series A Funding | FinSMEs
RheaVita, a Ghent, Belgium-based provider of freeze-drying technology for biopharmaceutical products, raised €2.5M in Series A funding
Thirty Madison Raises $140M in Series C Funding
Thirty Madison, a New York-based healthcare company that focuses on people with chronic conditions, raised $140M in Series C funding.
The round was led by new investor HealthQuest Capital with participation from Mousse Partners and Bracket Capital and existing investors Polaris Partners, Johnson & Johnson Innovation – JJDC, Inc., Northzone, Greycroft, and others. In conjunction with the funding, Randy Scott, Partner at HealthQuest Capital, will join Jason Stoffer, Partner at Maveron, and Amy Schulman, Managing Partner at Polaris Partners, as a member of Thirty Madison’s Board of Directors.
The company, which has raised a total of $210m to date and is now valued at over $1 billion, intends to use the funds to expand access to its care model for people who suffer from chronic conditions and enhance the capabilities of its proprietary platform.
Led by Steven Gutentag, co-founder and CEO, Thirty Madison is the premier healthcare company for people living with chronic conditions. Its specialized care model, powered by a proprietary platform, provides care to an increasing number of patients via:
- Keeps for men’s hair loss,
- Evens for gastrointestinal conditions,
- Cove for migraine, and
- Picnic for allergies.
Thirty Madison Raises $140M in Series C Funding | FinSMEs
Thirty Madison, a New York-based healthcare company that focuses on people with chronic conditions, raised $140M in Series C funding
Stablix Therapeutics Raises $63M in Series A Funding
Stablix Therapeutics, a New York based biotechnology company which specializes in Targeted Protein Stabilization (TPS), raised $63M in Series A funding.
The round was led by Versant Ventures with participation from NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities.
The company intends to use the funds to build out its platform and advance a portfolio of protein stabilizers towards the clinic.
Led by Carlo Rizzuto, Ph.D., acting CEO (and partner at Versant), Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s RESTORED platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.
Stablix Therapeutics Raises $63M in Series A Funding | FinSMEs
Stablix Therapeutics, a New York based biotechnology company which specializes in Targeted Protein Stabilization (TPS), raised $63M in Series A funding
Phil Raises $56M in Series D Funding
Phil, a San Francisco, CA-based provider of therapy deployment software for the pharma market, raised $56M in Series D funding.
The round is part of an arrangement for Warburg Pincus to invest up to $100 million. As part of the deal, Fred Hassan, Director at Warburg Pincus, will join Phil’s board of directors. Hassan has a multi-decade career in pharmaceuticals, including roles as CEO of Schering-Plough and Pharmacia, as well as Board roles at Bausch & Lomb, Precigen, Valeant and Avon Products. He currently serves as a Director of Amgen.
The company intends to use the funds to accelerate the development of products while continuing to support the growth of its customers.
Led by Deepak Thomas, Founder and CEO, Phil provides a software therapy deployment platform for manufacturers to control their distribution channels by streamlining and simplifying the complex, distributed workflow spanning patients, prescribers, pharmacies, insurers, and manufacturers.
Phil Raises $56M in Series D Funding | FinSMEs
Phil, a San Francisco, CA-based provider of therapy deployment software for the pharma market, raised $56M in Series D funding
Helix Raises $50M in Series C Funding
Helix, a San Mateo CA-based population genomics and COVID-19 testing company, raised $50M in Series C funding.
The round was led by Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek.
The company intends to use the funds to accelerate the organization’s population genomics platform across health systems, life sciences companies, and to continue COVID-19 testing and viral surveillance efforts.
Led by James Lu, MD, PhD, co-founder and CEO, Helix operates a CLIA-certified and-CAP-accredited sequencing laboratory, which powers both its Exome+® and COVID-19 viral sequencing efforts. Since its founding in 2015, the company has empowered hundreds of thousands of individuals to improve their lives through their DNA including through large-scale population health initiatives including Renown Health’s Healthy Nevada Project and Mayo Clinic’s Tapestry program.
Helix Raises $50M in Series C Funding | FinSMEs
Helix, a San Mateo CA-based population genomics and COVID-19 testing company, raised $50M in Series C funding
entrinsic bioscience Secures $49M in Financing
entrinsic bioscience (EBS), a Norwood, Mass.-based company that aims to discover and patent precise combinations of amino acids with broad health and wellness applications as functional ingredients and APIs, secured $49m in non-dilutive growth financing.
Jefferies Funding acted as sole lender to EBS. The event follows Series A and B round, including multiple rounds of investment from Johnson & Johnson INNOVATION | JJDC. Aon Plc, using its proprietary intellectual property (IP) valuation platform to value EBS’ IP portfolio, arranged for an IP Collateral Insurance policy for Jefferies, collateralized by EBS’ IP portfolio. Insurers involved include Allianz, Aspen, and Markel.
entrinsic bioscience (EBS) combines a proprietary IP platform and discovery engine to deliver next generation functional ingredients and Active Pharmaceutical Ingredients (APIs) designed to address multiple consumer health conditions and serious disease states. Immediate applications include programs for GI, Airway Diseases and Skin.
entrinsic bioscience Secures $49M in Financing | FinSMEs
entrinsic bioscience (EBS), a Norwood, Mass.-based company that aims to discover and patent precise combinations of amino acids with broad health and wellness applications as functional ingredients and APIs, secured $49m in non-dilutive growth financing
Hello Heart Raises $45M in Series C Funding
Hello Heart, a Menlo Park CA-based company which specializes in digital therapeutics solutions, raised $45M in Series C funding.
The round was led by IVP with participation from existing investors Khosla Ventures, BlueRun Ventures, Maven Ventures, and Resolute Ventures. In conjunction with the round, Somesh Dash, General Partner at IVP, will join Hello Heart’s Board of Directors.
The company intends to use the funds to scale teams and technology.
Founded in 2013 by Maayan Cohen, CEO, Hello Heart leverages technology to improve the way patients manage and understand their heart health and enables them to catch risk in time and avoid catastrophic events from home. To this end, the company developed a clinically-based smartphone solution used by dozens of F500 companies which offer Hello Heart to their employees. Users track key health metrics, receive personalized feedback, and take steps to improve their health with clinically proven suggestions, all through their smartphone.
Hello Heart Raises $45M in Series C Funding | FinSMEs
Hello Heart, a Menlo Park CA-based company which specializes in digital therapeutics solutions, raised $45M in Series C funding
Synchron Raises $40M in Series B Funding
Synchron, a New York-based company developer of brain interface platforms, raised $40M in series B funding.
The round, which brought the total amount raised since company formation to $59m, was led by Khosla Ventures with participation from Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital (Michael Auerbach), re.Mind Capital (Christian Angermayer), as well as individuals Arani Bose (Penumbra) and Thomas Reardon and existing investors NeuroTechnology Investors, METIS innovative, and the University of Melbourne.
The company intends to use the funds to launch U.S. clinical trials of minimally invasive brain computer interface following the conduction of human trials in Australia.
Led by CEO Thomas Oxley, MD, PhD., Synchron is a leader in minimally invasive implantable brain computer interface (BCI) technology, which utilizes the jugular vein to access the brain. The company has already commenced a clinical trial in Australia that has so far enrolled four patients with paralysis who have undergone implantation and are being assessed for their ability to control digital devices through thought to improve their functional independence.
Synchron Raises $40M in Series B Funding
Synchron, a New York-based company developer of brain interface platforms, raised $40M in series B funding
Nayya Raises $37M in Series B Funding
Nayya, a NYC-based insurance benefits experience and healthcare management platform, raised $37M in Series B financing.
The round, which brought total funding to just under $50M, was co-led by SVB Capital and ICONIQ Growth, with participation from investors Bow Capital, Felicis Ventures, Social Leverage and SemperVirens and returning investors Guardian Strategic Ventures and Unum Business Ventures, alongside health insurer CNO Financial Group.
The company intends to use the funds to grow the size of its team and invest in new features for its core offerings.
Co-founded in 2019 by Sina Chehrazi and Akash Magoon, Nayya provides:
Choose, a personalized decision support engine that helps employees select the right plans for their lifestyles during enrollment, and the newly launched Use product, an AI-driven, automated healthcare claims assistance and benefits engagement solution designed to help employees save money. Nayya’s employee engagement product tracks financial spending to guide and redirect consumers to file claims programmatically, manage spending accounts, and optimize prescription locations.
Nayya Raises $37M in Series B Funding
Nayya, a NYC-based insurance benefits experience and healthcare management platform, raised $37M in Series B financing
Standard Bariatrics Raises $35M in Series B Funding
Standard Bariatrics, Inc., a Cincinnati, OH-based bariatric surgery medical device company, raised $35M in Series B funding.
The round was led by U.S. Venture Partners (USVP) with participation from new investor River Cities Capital, RiverVest® Venture Partners, Hatteras Venture Partners, Queen City Angels and Emergent Medical Partners.
Led by CEO Matt Sokany, Standard Bariatrics has developed the Titan SGS™, a design that offers surgeons performing sleeve gastrectomy, a bariatric surgical procedure for obesity disease. In April of 2021, the company’s Titan SGS™ stapler received clearance from the US Food and Drug Administration allowing the device to be used in bariatric surgery requiring the creation of sleeve pouch anatomy (sleeve gastrectomy). The submission was supported by the completion of a successful 62-patient study.
Standard Bariatrics Raises $35M in Series B Funding | FinSMEs
Standard Bariatrics, Inc., a Cincinnati, OH-based bariatric surgery medical device company, raised $35M in Series B funding
Zenflow Raises $24M in Series B Funding
Zenflow, Inc., a South San Francisco, CA-based medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), closed a $24m Series B financing round.
The round was led by Invus Opportunities with participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia Angels, CloudStone Capital, SV Tech Ventures, and others.
Led by Nick Damiano, Co-Founder and CEO, Zenflow is a medical device company dedicated to improving treatment for patients suffering from urinary obstruction caused by enlarged prostate.
Zenflow intends to use the funds for pivotal clinical trial and FDA clearance of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
Zenflow Raises $24M in Series B Funding | FinSMEs
Zenflow, Inc., a South San Francisco, CA-based medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), closed a $24m Series B financing round
Small Door Veterinary Raises $20M in Series A Funding
Small Door Veterinary, a New York-based membership veterinary care company, raised $20M in Series A funding.
The was led by Toba Capital, with participation from Pentland Group, and existing investors Lerer Hippeau, Primary Ventures, Brand Foundry, Howard Draft, Zach Weinberg and Nat Turner.
The company intends to use the funds to expand operations and its business reach.
Co-founded by Josh Guttman and Florent Peyre, Small Door Veterinary is a veterinary care company whose membership includes care, 24/7 telemedicine, and transparent pricing – delivered with hospitality in spaces designed by animal experts. The company opened its first location in Manhattan’s West Village in early 2020, will open its second practice on Manhattan’s Upper East Side in 2021 and plans to open 25 locations by 2025.
Small Door Veterinary Raises $20M in Series A Funding
Small Door Veterinary, a New York-based membership veterinary care company, raised $20M in Series A funding
Myra Vision Raises $17M In Series A Financings
Myra Vision, a Campbell, Calif.-based maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financings.
The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors.
Led by Robert Chang, CEO of Myra Vision is developing novel technology designed to allow safe outflow control to achieve maximum intraocular pressure (IOP) reduction while also reducing complexity and complication rates.
The company intends to use the funds to advance product development, scale infrastructure, and expand the team in order to support the development of its glaucoma treatment device.
In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc.
Myra Vision Raises $17M In Series A Financings
Myra Vision, a Campbell, Calif.-based maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financings
Stellanova Therapeutics Closes $15.5M Series A Financing Round
Stellanova Therapeutics, Inc., a Houston, TX-based biotechnology company advancing cancer therapies targeting the tumor microenvironment, closed a $15.5m Series A financing.
The round was led by Sporos Bioventures.
The company intends to use the funds to advance its lead antibody asset to first-in-human clinical trials for oncology, establish its discovery platform, and build its team.
Led by Rosa Hwang, M.D., co-founder, Stellanova is focused on targeting the many pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. CAFs play essential roles in promoting cancer growth and metastasis, spurring angiogenesis, suppressing anti-tumor immunity, and fostering chemoresistance. The company’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. In pre-clinical studies, treatment with anti-DKK3 monoclonal antibody and immune checkpoint inhibitor therapy has produced sustained tumor eradication in mouse models of pancreatic cancer which is refractory to current chemo or immune therapies.
Stellanova Therapeutics Closes $15.5M Series A Financing Round
Stellanova Therapeutics, Inc., a Houston, TX-based biotechnology company advancing cancer therapies targeting the tumor microenvironment, closed a $15.5m Series A financing
Prixa Raises $3M in Funding
Prixa, an Indonesian health tech startup, raised $3m in funding.
The round was led by Telkom Indonesia’s MDI Ventures and Trans-Pacific Technology Fund, with participation from Siloam Hospitals Group.
The company intends to use the funds to continue to expand operations and its business reach.
Founded in 2019 by CEO James Roring, Prixa provides an AI powered health management platform which allows users to book virtual meetings with doctors, request lab tests and have medicines delivered. The company partners with insurance companies, corporations and government entities and serves approx. 10 million users.
Prixa Raises $3M in Funding
Prixa, an Indonesian health tech startup, raised $3m in funding.
Ark Surgical Raises $2.1M in Funding
Ark Surgical, a Nazareth, Israel-based femtech startup, raised $2.1M in funding.
The round was led by investors via the Together equity crowdfunding platform alongside the Israeli Innovation Authority and NGT.
The company intends to use the funds to continue to develop its solution and move in its pathway to the market.
Led by CEO Stav Tori, Ark Surgical is advancing the LapBox™ containment system for secure removal of large internal organs during laparoscopic GYN surgery. LapBox serves as a fully contained space within the inflated abdomen within which the surgeon can effectively morcellate large organs such as the uterus, without the risks associated with tissue morcellation.